<DOC>
	<DOCNO>NCT00294515</DOCNO>
	<brief_summary>This study determine relative efficacy safety 100 day Valcyte prophylaxis relative 200 day Valcyte prophylaxis give prevention CMV disease high-risk ( D+/R- ) kidney allograft recipient . The anticipated time study treatment 3-12 month target sample size 100-500 individual .</brief_summary>
	<brief_title>IMPACT Study : A Study Valcyte ( Valganciclovir ) Prevention Cytomegalovirus Disease ( CMV ) Kidney Allograft Recipients</brief_title>
	<detailed_description />
	<mesh_term>Cytomegalovirus Infections</mesh_term>
	<mesh_term>Valganciclovir</mesh_term>
	<mesh_term>Ganciclovir</mesh_term>
	<criteria>â‰¥ 16 year age CMV seronegative recipient primary secondary renal allograft live cadaveric seropositive donor Adequate hematological renal function Patients partner must agree maintain effective birth control 90 day follow cessation study medication CMV disease , receipt antiCMV therapy within 30 day prior screen Multiorgan transplant recipient Hepatitis B , hepatitis C HIV positive Women pregnant lactating</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2010</verification_date>
</DOC>